Literature DB >> 19804366

Coagulation factor XIII variants with altered thrombin activation rates.

Mette Dahl Andersen1, Marianne Kjalke, Susanne Bang, Inger Lautrup-Larsen, Peter Becker, Asser Sloth Andersen, Ole Hvilsted Olsen, Henning R Stennicke.   

Abstract

Coagulation factor XIII (FXIII) is activated by thrombin and catalyses crosslinking between fibrin monomers thereby providing mechanical strength to the fibrin network. V34L is a common FXIII-A polymorphism found in the activation peptide. FXIII-A V34L is activated faster by thrombin and provides formation of a tighter clot at fibrinogen concentrations in the low end of the physiological range. FXIII-A variants with potentially increased activation rates were generated. Introduction of an optimal thrombin cleavage site, V34L+V35T, increased the activation rate 7.6-fold and facilitated the formation of a fibrin network more resistant to fibrinolysis than obtained with wt FXIII-A. In contrast, introduction of fragments of fibrinopeptide A into the activation peptide resulted in severely impaired activation rates.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19804366     DOI: 10.1515/BC.2009.142

Source DB:  PubMed          Journal:  Biol Chem        ISSN: 1431-6730            Impact factor:   3.915


  5 in total

1.  Effects of introducing fibrinogen Aalpha character into the factor XIII activation peptide segment.

Authors:  Madhavi A Jadhav; Giulia Isetti; Toni A Trumbo; Muriel C Maurer
Journal:  Biochemistry       Date:  2010-04-06       Impact factor: 3.162

2.  Screening cleavage of Factor XIII V34X Activation Peptides by thrombin mutants: A strategy for controlling fibrin architecture.

Authors:  Madhavi A Jadhav; Whitney N Goldsberry; Sara E Zink; Kelsey N Lamb; Katelyn E Simmons; Carmela M Riposo; Boris A Anokhin; Muriel C Maurer
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-07-04       Impact factor: 3.036

Review 3.  Staphylococcus aureus secretes coagulase and von Willebrand factor binding protein to modify the coagulation cascade and establish host infections.

Authors:  Molly McAdow; Dominique M Missiakas; Olaf Schneewind
Journal:  J Innate Immun       Date:  2012-01-03       Impact factor: 7.349

4.  New developments in the management of congenital Factor XIII deficiency.

Authors:  Zehra Fadoo; Quratulain Merchant; Karim Abdur Rehman
Journal:  J Blood Med       Date:  2013-05-28

Review 5.  Catridecacog: a breakthrough in the treatment of congenital factor XIII A-subunit deficiency?

Authors:  Wolfgang Korte
Journal:  J Blood Med       Date:  2014-07-09
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.